ACM
KYMR icon

Aster Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Aster Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-112
Closed -$3.06K – 1073
2026
Q1 		$3.06K Buy
+112
New +$8.87K ﹤0.01% 729
2025
Q3 		– Sell
-5,661
Closed -$247K – 1185
2025
Q2 		$247K Buy
5,661
+3,945
+230% +$136K 0.06% 333
2025
Q1 		$53.8K Buy
1,716
+1,629
+1,872% +$59.4K 0.01% 803
2024
Q4 		$3.5K Buy
+87
New +$3.93K ﹤0.01% 905

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Aster Capital Management's KYMR Position: Q2 2026 in Review

Aster Capital Management sold out of Kymera Therapeutics (KYMR) in Q2 2026, closing a stake of 112 shares — an estimated $3.06K sold.

Aster Capital Management first reported a position in KYMR in Q4 2024 and held it in 4 quarters. The position peaked at $247K in Q2 2025. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Aster Capital Management reported no remaining Kymera Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Aster Capital Management sold 112 Kymera Therapeutics shares in Q2 2026, an estimated $3.06K.
  • Aster Capital Management first reported a position in Kymera Therapeutics in Q4 2024 and held it in 4 quarters.
  • Aster Capital Management's Kymera Therapeutics position peaked at $247K in Q2 2025.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.